Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Get Full Regulatory Alignment Or See Post-Brexit Declines In Trials, Manufacturing, Product Launches, Says UK Committee

Executive Summary

Stakeholders that gave evidence to a UK parliamentary inquiry into the impact of Brexit on medicines and medical devices said full regulatory alignment was vital if the UK was to avoid declines in clinical trial and manufacturing activity and delays in the launch of new drugs.

Advertisement

Related Content

UK Biotech Not Impressed By Govt’s Response To MPs’ Brexit Concerns
UK’s Future Access To EU Trials Portal ‘Outside Our Control,’ Says Govt
UK Health Committee Wants Clear Answers On Future Links Between MHRA And EMA
Post-Brexit UK Could Lose Access To EU’s Drug Safety Database
UK Pharma Execs Urged To Be More Outspoken About Brexit ‘Disaster’

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122749

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel